Panacea Biotec Announces Audited Financial Results and Appoints New Independent Director

Panacea Biotec Announces Audited Financial Results and Appoints New Independent Director​

Panacea Biotec Limited announced the approval of its standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. Additionally, the company's Board of Directors passed over a dividend for the fiscal year 2025-26 and approved the appointment of Mr. Rajinder Singh Manku as a non-executive independent director.

The Board of Directors reviewed the financial results at its meeting held on May 30, 2026. The results, which cover the quarter and full year ended March 31, 2026, are available alongside the Auditors' Report.

Key Financial Results Overview​

The company reported the following key financial figures for the quarter and year ended March 31, 2026:

Segmental and Balance Sheet Details​

The company's consolidated financial results for the quarter and year ended March 31, 2026, showed a total segment revenue of 16,675 (Quarter Ended March 31, 2026) and 63,977 (Year Ended March 31, 2026).

The consolidated balance sheet structure as of March 31, 2026, reported Total Assets of 1,26,217 (₹ in Lakh) and Total Equity and Liabilities of 1,26,217 (₹ in Lakh). Key components included:

Board Decisions​

During the meeting, the Board of Directors took two material decisions:

1. Dividend Passing Over: The Board approved passing over the dividend on both equity shares and preference shares for the financial year 2025-26, citing losses incurred during the year.
2. New Director Appointment: Mr. Rajinder Singh Manku was appointed as an additional director in the capacity of a non-executive independent director, not liable to retire by rotation. His term of appointment is for 5 consecutive years, effective from July 01, 2026, subject to shareholder approval.

Appointment Details​

Mr. Rajinder Singh Manku, who was appointed as an additional director, is not related to any existing director of the company. He holds a bachelor's degree in mechanical engineering and law, along with post graduate diplomas in Sales & Marketing, Materials Management, and Export-Import Management, and a Master of Business Administration (Finance). He brings approximately 37 years of diverse experience in areas including project planning and execution, strategic business development, procurement & supply chain management, stakeholder management, and finance.

The appointment is effective from July 01, 2026, for a term of 5 years.

PANACEABIO Stock Price Movement​

On Friday, Panacea Biotec Limited shares slipped by 0.52%, settling at ₹412.85 for the session. The stock traded on a volume of 99,419 shares, having ranged between ₹409.05 and ₹427.4.